Form 4 for LCTX Lineage Cell Therapeutics, Inc.

Accepted 2024-02-08 00:00:00 ET · period of report 2024-02-06 · accession 0000919574-24-000757 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
I	2024-02-08	2024-02-06	LCTX	BROADWOOD PARTNERS, L.P.	Dir, 10%	P - Purchase	—	0	41.67M	New	—
	2024-02-08	2024-02-06	LCTX	BROADWOOD PARTNERS, L.P.	Dir, 10%	P - Purchase	$1.04	+6.73M	41.67M	+19%	+$7.00M

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Shares	2024-02-06	P	A	0	$0.00	41,666,255	I	—	—
2	Common	Common Shares	2024-02-06	P	A	6,730,770	$1.04	41,666,255	D See Footnote	—	—	(F2) On February 6, 2024, Broadwood Partners entered into a Stock Purchase Agreement with Lineage Cell Therapeutics, Inc. (the "Issuer") pursuant to which Broadwood Partners agreed to acquire 6,730,770 shares of the Issuer's Common Stock, no par value (the "Common Shares"), from the Issuer in its registered direct offering for a total purchase price of $7,000,000.80, or $1.04 per Common Share. (F1) The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed beneficially owned by Broadwood Capital, Inc. as General Partner of Broadwood Partners and Neal C. Bradsher as President of Broadwood Capital, Inc. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.